Abstract
The accurate and early diagnosis and classification of cancer origin from either tissue or liquid biopsy is crucial for selecting the appropriate treatment and reducing cancer-related mortality. Here, we established the CAncer Cell-of-Origin (CACO) methylation panel using the methylation data of the 28 types of cancer in The Cancer Genome Atlas (7950 patients and 707 normal controls) as well as healthy whole blood samples (95 subjects). We showed that the CACO methylation panel had high diagnostic potential with high sensitivity and specificity in the discovery (maximum AUC = 0.998) and validation (maximum AUC = 1.000) cohorts. Moreover, we confirmed that the CACO methylation panel could identify the cancer cell type of origin using the methylation profile from liquid as well as tissue biopsy, including primary, metastatic, and multiregional cancer samples and cancer of unknown primary, independent of the methylation analysis platform and specimen preparation method. Together, the CACO methylation panel can be a powerful tool for the classification and diagnosis of cancer.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Code availability
Custom R scripts used to analyze microarray and NGS data are available from the corresponding authors upon reasonable request.
Data availability
Microarray data (IDAT files) have been deposited into the DDBJ Genomic Expression Archive (GEA). GEA accession: E-GEAD-396. tPBAT data (fastq files) have been deposited into the DDBJ Sequence Read Archive (DRA). DRA accession: DRA010902. All other raw data that are not found in the supplementary information are available from the corresponding authors upon reasonable request.
References
Fitzmaurice C, Akinyemiju TF, Al Lami FH, Alam T, Alizadeh-Navaei R, Allen C, et al. Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 29 cancer groups, 1990 to 2016 a systematic analysis for the global burden of disease study global burden of disease cancer collaboration. JAMA Oncol. 2018;4:1553–68.
Hoadley KA, Yau C, Hinoue T, Wolf DM, Lazar AJ, Drill E, et al. Cell-of-origin patterns dominate the molecular classification of 10,000 tumors from 33 types of cancer. Cell. 2018;173:291–304. e6
Hoadley KA, Yau C, Wolf DM, Cherniack AD, Tamborero D, Ng S, et al. Multiplatform analysis of 12 cancer types reveals molecular classification within and across tissues of origin. Cell. 2014;158:929–44.
Han L, Yuan Y, Zheng S, Yang Y, Li J, Edgerton ME, et al. The Pan-cancer analysis of pseudogene expression reveals biologically and clinically relevant tumour subtypes. Nat Commun 2014;5. https://doi.org/10.1038/ncomms4963.
Akbani R, Ng PKS, Werner HMJ, Shahmoradgoli M, Zhang F, Ju Z, et al. A pan-cancer proteomic perspective on the cancer genome atlas. Nat Commun 2014; 5. https://doi.org/10.1038/ncomms4887.
Stroun M, Maurice P, Vasioukhin V, Lyautey J, Lederrey C, Lefort F, et al. The origin and mechanism of circulating DNA. Ann N Y Acad Sci. 2000;906:161–8.
Schwarzenbach H, Hoon DSB, Pantel K. Cell-free nucleic acids as biomarkers in cancer patients. Nat Rev Cancer 2011;11:426–37.
Francis G, Stein S. Circulating cell-free tumour DNA in the management of cancer. Int J Mol Sci 2015;16:14122–42.
Jaenisch R, Bird A. Epigenetic regulation of gene expression: how the genome integrates intrinsic and environmental signals. Nat Genet 2003;33:245–54.
Esteller M. Epigenetics in cancer. N. Engl J Med. 2008;358:1148–59.
Jones PA, Baylin SB. The epigenomics of cancer. Cell. 2007;128:683–92.
Baylin SB, Jones PA. Epigenetic determinants of cancer. Cold Spring Harb Perspect Biol. 2016;8:a019505.
Irizarry RA, Ladd-Acosta C, Wen B, Wu Z, Montano C, Onyango P, et al. The human colon cancer methylome shows similar hypo- and hypermethylation at conserved tissue-specific CpG island shores. Nat Genet. 2009;41:178–86.
Baylin SB, Jones PA. A decade of exploring the cancer epigenome-biological and translational implications. Nat Rev Cancer 2011;11:726–34.
Field AE, Robertson NA, Wang T, Havas A, Ideker T, Adams PD. DNA methylation clocks in aging: categories, causes, and consequences. Mol Cell 2018;71:882–95.
Hao X, Luo H, Krawczyk M, Wei W, Wang W, Wang J, et al. DNA methylation markers for diagnosis and prognosis of common cancers. Proc Natl Acad Sci USA. 2017;114:7414–9.
Witte T, Plass C, Gerhauser C. Pan-cancer patterns of DNA methylation. Genome Med 2014;6:66.
Ding W, Chen G, Shi T. Integrative analysis identifies potential DNA methylation biomarkers for pan-cancer diagnosis and prognosis. Epigenetics. 2019;14:67–80.
Liu B, Liu Y, Pan X, Li M, Yang S, Li SC. DNA methylation markers for pan-cancer prediction by deep learning. Genes (Basel). 2019;10:778.
Guo S, Diep D, Plongthongkum N, Fung HL, Zhang K, Zhang K. Identification of methylation haplotype blocks AIDS in deconvolution of heterogeneous tissue samples and tumor tissue-of-origin mapping from plasma DNA. Nat Genet. 2017;49:635–42.
Xu RH, Wei W, Krawczyk M, Wang W, Luo H, Flagg K, et al. Circulating tumour DNA methylation markers for diagnosis and prognosis of hepatocellular carcinoma. Nat Mater. 2017;16:1155–62.
Luo H, Zhao Q, Wei W, Zheng L, Yi S, Li G, et al. Circulating tumor DNA methylation profiles enable early diagnosis, prognosis prediction, and screening for colorectal cancer. Sci Transl Med. 2020;12:eaax7533.
Nuzzo PV, Berchuck JE, Korthauer K, Spisak S, Nassar AH, Abou Alaiwi S, et al. Detection of renal cell carcinoma using plasma and urine cell-free DNA methylomes. Nat Med. 2020;26:1041–3.
Shen SY, Singhania R, Fehringer G, Chakravarthy A, Roehrl MHA, Chadwick D, et al. Sensitive tumour detection and classification using plasma cell-free DNA methylomes. Nature. 2018;563:579–83.
Liu L, Toung J, Jassowicz A, Vijayaraghavan R, Kang H, Zhang R, et al. Targeted methylation sequencing of plasma cell-free DNA for cancer detection and classification. Ann Oncol J Eur Soc Med Oncol. 2018;29:1445–53.
Cokus SJ, Feng S, Zhang X, Chen Z, Merriman B, Haudenschild CD, et al. Shotgun bisulphite sequencing of the Arabidopsis genome reveals DNA methylation patterning. Nature. 2008;452:215–9.
Lister R, O’Malley RC, Tonti-Filippini J, Gregory BD, Berry CC, Millar AH, et al. Highly integrated single-base resolution maps of the epigenome in Arabidopsis. Cell. 2008;133:523–36.
Miura F, Enomoto Y, Dairiki R, Ito T. Amplification-free whole-genome bisulfite sequencing by post-bisulfite adaptor tagging. Nucleic Acids Res. 2012;40:e136.
Miura F, Shibata Y, Miura M, Sangatsuda Y, Hisano O, Araki H, et al. Highly efficient single-stranded DNA ligation technique improves low-input whole-genome bisulfite sequencing by post-bisulfite adaptor tagging. Nucleic Acids Res. 2019;47:e85.
Lawson DA, Kessenbrock K, Davis RT, Pervolarakis N, Werb Z. Tumour heterogeneity and metastasis at single-cell resolution. Nat Cell Biol 2018;20:1349–60.
McGranahan N, Swanton C. Clonal heterogeneity and tumor evolution: past, present, and the future. Cell. 2017;168:613–28.
Turajlic S, Sottoriva A, Graham T, Swanton C. Resolving genetic heterogeneity in cancer. Nat Rev Genet 2019;20:404–16.
Reiter JG, Baretti M, Gerold JM, Makohon-Moore AP, Daud A, Iacobuzio-Donahue CA, et al. An analysis of genetic heterogeneity in untreated cancers. Nat Rev Cancer. 2019;19:639–50.
Uchi R, Takahashi Y, Niida A, Shimamura T, Hirata H, Sugimachi K, et al. Integrated multiregional analysis proposing a new model of colorectal cancer evolution. PLOS Genet. 2016;12:e1005778.
Moss J, Magenheim J, Neiman D, Zemmour H, Loyfer N, Korach A, et al. Comprehensive human cell-type methylation atlas reveals origins of circulating cell-free DNA in health and disease. Nat Commun 2018; 9. https://doi.org/10.1038/s41467-018-07466-6.
Varadhachary GR, Raber MN. Cancer of unknown primary site. N. Engl J Med. 2014;371:757–65.
Briasoulis E, Tolis C, Pavlidis N. ESMO minimum clinical recommendations for diagnosis, treatment and follow-up of cancers of unknown primary site (CUP). Ann Oncol. 2001;12:1057–8.
Pavlidis N, Pentheroudakis G. Cancer of unknown primary site. Lancet. 2012;379:1428–35.
Moran S, Martinez-Cardús A, Boussios S, Esteller M. Precision medicine based on epigenomics: the paradigm of carcinoma of unknown primary. Nat Rev Clin Oncol 2017;14:682–94.
Moran S, Martínez-Cardús A, Sayols S, Musulén E, Balañá C, Estival-Gonzalez A, et al. Epigenetic profiling to classify cancer of unknown primary: a multicentre, retrospective analysis. Lancet Oncol. 2016;17:1386–95.
Zhu B, Poeta ML, Costantini M, Zhang T, Shi J, Sentinelli S, et al. The genomic and epigenomic evolutionary history of papillary renal cell carcinomas. Nat Commun 2020; 11. https://doi.org/10.1038/s41467-020-16546-5.
Benson C, Miah AB. Uterine sarcoma - current perspectives. Int J Women’s Health 2017;9:597–606.
Shen SY, Burgener JM, Bratman SV, De Carvalho DD. Preparation of cfMeDIP-seq libraries for methylome profiling of plasma cell-free DNA. Nat Protoc. 2019;14:2749–80.
Liu Y, Siejka-Zielińska P, Velikova G, Bi Y, Yuan F, Tomkova M, et al. Bisulfite-free direct detection of 5-methylcytosine and 5-hydroxymethylcytosine at base resolution. Nat Biotechnol. 2019;37:424–9.
C H. Statistical analysis for toxicity studies. J Toxicol Pathol. 2018;31:15–22.
Acknowledgements
The images in Fig. 1a and Supplementary Fig. S1b are from TogoTV (© 2016 DBCLS TogoTV) and Pintarest.
Funding
D.S. was supported by JSPS KAKENHI Grant Number 19K16868. K.M. received funding from the Platform Project for Supporting Drug Discovery, Life Science Research (Basis for Supporting Innovative Drug Discovery and Life Science Research (BINDS)) from AMED under Grant Number JP20am0101103 (support number 0958), P-CREATE from AMED (20cm0106475h0001(e-Rad ID: 20317791)), JSPS KAKENHI (20H05039, 19H03715, 19K09220), Grant-in-Aid for Scientific Research on Innovative Areas (15H05912), Priority Issue on Post-K computer (hp170227, hp160219), the Project for Cancer Research and Therapeutic Evolution (19cm0106504h0004), Research Grant of the Princess Takamatsu Cancer Research, and SRL, Miraka Research Institute and Takeda Science Foundation. K.T. was supported by the Kobayashi Foundation, Takeda Science Foundation and JSPS KAKENHI Grant Number (21H02758 and 21K19402).
Author information
Authors and Affiliations
Contributions
D.S. and K.T. conceived and designed the research. D.S. performed most of the bioinformatics analysis with assistance from K.T., Y.M., H.H., M.S., and A.N. M.F., K.S., Y.M., Y.K., M.S., and H.B. collected, analyzed, and interpreted the clinical data. K.T., S.T., and A.K. performed the microarray experiments. H.A., F.M., and T.I. performed the PBAT analysis. Y.K., A.K., Y.Y., K.S., T.S., S.I., T.M., M.S., H.B., N.A., and Y.K. provided guidance and scientific input. D.S., K.T., and K.M. wrote the paper.
Corresponding authors
Ethics declarations
Competing interests
K.T., S.T., and A.K. were employees of Genomedia Inc. The remaining authors declare no competing interests.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary information
Rights and permissions
About this article
Cite this article
Shimizu, D., Taniue, K., Matsui, Y. et al. Pan-cancer methylome analysis for cancer diagnosis and classification of cancer cell of origin. Cancer Gene Ther 29, 428–436 (2022). https://doi.org/10.1038/s41417-021-00401-w
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41417-021-00401-w
This article is cited by
-
Hierarchical classification-based pan-cancer methylation analysis to classify primary cancer
BMC Bioinformatics (2023)
-
Current status of molecular diagnostic approaches using liquid biopsy
Journal of Gastroenterology (2023)
-
ZNF92, an unexplored transcription factor with remarkably distinct breast cancer over-expression associated with prognosis and cell-of-origin
npj Breast Cancer (2022)